A study that was recently published in the “International Journal of Urological Nursing” found that intravesical therapy affected the physical, emotional and social well-being of patients who suffered from non-muscle invasive bladder cancer. The participants of the study underwent intravesical therapy together with either mitomycine (“MMC”) or Bacillus Calmette-Guerin (“BCG”) treatments. The objective of the authors of the study was to evaluate the psychosocial issues these study subjects experienced during therapy and what effects those challenges triggered.
In their report, the authors stated that the patients struggled to cope with treatment side effects, adding that this was in addition to having to cope with relationships, family and work, which caused them even more stress.
For their study, the researchers conducted an analysis of data collected from 80 participants who were between 40 and 94 years of age. The data had been collected at the Franciscus Gasthuis hospital’s urological department between June 2013 and July 2014 from patients who had already begun or were beginning treatment with MMC or BCG intravesical therapy. Male participants made up more than 80% of the study population. The data, which was gathered through questionnaires, was analyzed using psychosocial distress and tools used to screen symptoms.
The researchers found that intravesical therapy affected the magnitude of distress of more than 30% of the participants, with a focus on their physical, emotional and social well-being. They also discovered that the therapy strained roughly 16% of the patients’ sexuality and about 5% of the patients’ relationships. In addition, nearly 10% of patients reported that the therapy negatively affected their transportation, with another 4%, 2.5% and about 6%, revealing that it also impacted their child-care, finances and work, respectively.
In their report, the researchers stated that patients between the ages of 40 and 59 experienced the highest levels of distress; the researchers noted that the stress could be associated with work-related issues or the challenges of childcare. The study’s participants also reported that self-confidence, anxiety, concentration, gloom or depression and dealing with emotions in general, caused them distress. However, they indicated that they hadn’t found it necessary to visit a mental health practitioner for help with these issues.
The authors explained in their report that nurses needed to remain aware of the psychosocial challenges patients dealt with during therapy as nurses’ awareness played a crucial role in availing the needed information and counseling, which would help patients maintain a higher quality of life during the treatment’s duration. They also noted that nurses played a major role in urging patients to take part in physical activity, which also seemed to have a beneficial effect on patients’ well-being during their treatment.
The field of bladder cancer treatment is evolving rapidly, and the technologies made by companies such as Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) make it easier for oncological surgeons to get a clearer view while performing procedures to remove bladder cancer tissues.
NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.